
China Joins ICH Global Harmonization Efforts
The China Food and Drug Administration has submitted its membership to the International Council for Harmonization.
On August 9, 2017, in an FDAVoice
During FDA’s meeting with CFDA, the agencies discussed the modernization of regulatory review systems and the importance of international collaboration to ensure consistent standards worldwide. China, like other countries, faces similar challenges to ensuring safe and effective drug products. According to FDA, CFDA has implemented changes to its regulations to align its standards to other global standards in order to address these challenges, including reforming its drug review system and implementing ICH guidelines.
ICH, which was established in 1990, has worked to standardize and evaluate drug development practices to ensure the development and manufacture of safe and effective medicines throughout the world. Harmonization of standards will ensure that different markets are held to the same standards throughout the world. CFDA’s membership in ICH will help ensure that goal.
“CFDA’s membership in ICH marks a significant milestone in expanding ICH’s impact and promoting global public health,” said Mullin in the blog post. FDA and CFDA will continue to discuss modernization later in 2017.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.